




Article

Metabolomics-Based Profiling via a Chemometric Approach to Investigate the Antidiabetic Property of Different Parts and Origins of *Pistacia lentiscus* L.

Chabha Sehaki ^{1,2}, Roland Molinie ¹ , David Mathiron ³ , Jean-Xavier Fontaine ¹ , Nathalie Jullian ¹,
Fadila Ayati ², Farida Fernane ²  and Eric Gontier ^{1,*} 

¹ BIOPI-UPJV Laboratory UMRT BioEcoAgro INRAE1158, SFR Condorcet FR CNRS 3417, UFR of Sciences, University of Picardie Jules Verne, 33 Rue Saint Leu, 80000 Amiens, France

² Laboratory of Natural Resources, University Mouloud Mammeri of Tizi-Ouzou, Tizi-Ouzou 15000, Algeria

³ Analytical Platform, UFR of Sciences, University of Picardie Jules Verne, 33 Rue Saint Leu, 80000 Amiens, France

* Correspondence: eric.gontier@u-picardie.fr; Tel.: +33-6-59-21-81-08

Abstract: *Pistacia lentiscus* L. is a medicinal plant that grows spontaneously throughout the Mediterranean basin and is traditionally used to treat diseases, including diabetes. The aim of this work consists of the evaluation of the α -glucosidase inhibitory effect (i.e., antidiabetic activity in vitro) of different extracts from the leaves, stem barks and fruits of *P. lentiscus* harvested on mountains and the littoral of Tizi-Ouzou in Algeria. Metabolomic profiling combined with a chemometric approach highlighted the variation of the antidiabetic properties of *P. lentiscus* according to the plant's part and origin. A multiblock OPLS analysis showed that the metabolites most involved in α -glucosidase inhibition activity were mainly found in the stem bark extracts. The highest inhibitory activity was found for the stem bark extracts, with averaged inhibition percentage values of 84.7% and 69.9% for the harvested samples from the littoral and mountain, respectively. On the other hand, the fruit extracts showed a lower effect (13.6%) at both locations. The UHPLC-ESI-HRMS characterization of the metabolites most likely responsible for the α -glucosidase-inhibitory activity allowed the identification of six compounds: epigallocatechin(4a>8)epigallocatechin (two isomers), (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (two isomers), 3,5-O-digalloylquinic acid and dihydroxy benzoic acid pentoside.

Keywords: *P. lentiscus*; α -glucosidase; phytochemical profiling; UHPLC-ESI-HRMS; metabolomic approach; antidiabetic



Citation: Sehaki, C.; Molinie, R.; Mathiron, D.; Fontaine, J.-X.; Jullian, N.; Ayati, F.; Fernane, F.; Gontier, E. Metabolomics-Based Profiling via a Chemometric Approach to Investigate the Antidiabetic Property of Different Parts and Origins of *Pistacia lentiscus* L. *Metabolites* **2023**, *13*, 275. <https://doi.org/10.3390/metabo13020275>

Academic Editor: Markus R. Meyer

Received: 18 December 2022

Revised: 3 February 2023

Accepted: 7 February 2023

Published: 14 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Statistics on people diagnosed with diabetes reveal that diabetes is a worldwide disease [1]. This disease affects approximately 5% of the world's population [2]. Diabetes mellitus (type 1) is characterized by chronic hyperglycemia caused by insufficient insulin secretion [3], whereas diabetes (type 2) is a metabolic disease resulting from the dynamic interaction between defects in insulin secretion and insulin action [2]. This insulin deficiency due to the dysfunction of pancreatic β cells [4] leads to increased glucose concentrations in the blood. Several drugs, such as sulfonylureas and biguanides, are used to lower blood glucose levels in diabetics. Among these classes, there are inhibitors of α -glucosidase, an enzyme responsible for the hydrolysis of carbohydrates to allow the passage of glucose into the bloodstream [5]. Currently, acarbose, miglitol and voglibose belong to classes of competitive α -glucosidase inhibitors in the intestine [6], reducing postprandial hyperglycemia. However, the use of these drugs has shown many side effects and toxicities [7]. It causes diarrhea [8] and adverse digestive disorders [8,9]. It has also been reported that acarbose can induce hepatitis [10,11] and increase liver enzyme levels [12].

Recent scientific research has shown that natural products could have an important hypoglycemic effect and could be alternatives for the treatment of type 2 diabetes. The plant families, which enclose the species, studied the most as inhibitors of α -glucosidase, based on a review by Benalla et al. (2010) [1], are Fabaceae, Crassulaceae, Hippocrateaceae, Lamiaceae and Myrtaceae. These studies have revealed the importance of medicinal plants as natural sources of antidiabetic bioactive agents. *P. lentiscus* (lentisk or mastic tree), a medicinal plant growing in the wild in the Mediterranean area [13,14] and belonging to the Anacardiaceae family, is traditionally used to treat hypertension, cough, sore throat, eczema, stomach ache, toothache, kidney disorders, jaundice [15], skin problems and diarrhea [16,17], but also diabetes [18]. In the ethnobotanical investigation on antidiabetic plants conducted in Morocco by Bouyahya et al. (2021), it was revealed that lentisk leaves were the most used part. In traditional medicine, for the treatment of diabetes, the administration of lentisk extract is conducted orally; leaf decoction is the main mode of preparation, followed by infusion. The phytochemistry of lentisk has been extensively studied using high-performance liquid chromatography–mass spectrometry (HPLC-MS). Several phenolic acids have been detected, such as gallic acid, quinic acid and galloyl derivatives [19–23], as well as flavonoid glycoside compounds [21].

Recent investigations have focused on the study of phytochemical profiling and the multibiological potential of plant extracts via integrated approaches [24,25]. The researchers in these studies were interested in metabolomic analyses to characterize metabolites in plants that may be responsible for particular bioactive activities, such as antioxidant and in vitro antidiabetic activities [26–28].

Even though there are many ethnobotanical pharmaceutical uses of *P. lentiscus* [29], very few studies [23,30] have been carried out to explore the possibilities of using this species as an antidiabetic agent. These studies were carried out by Foddai et al. [30] on aqueous leaf and fruits extract and Mehenni et al. [23] on ethanolic extracts. Most of the research on *P. lentiscus* has been conducted to find out its antioxidant [31–37], antimicrobial [38–41], anticancer [22,42–44] and anti-inflammatory potential [19,45–47]. So far, no study has reported a metabolomic analysis to identify inhibitors of antidiabetic potential in different lentisk organs. It is known that different geographical regions can affect the composition and biological activity of plants [48]. Therefore, our study is the first work that aimed to achieve the following:

- (i) Evaluate α -glucosidase inhibition in *P. lentiscus* samples and identify compounds more positively correlated to α -glucosidase inhibition using a metabolomic approach;
- (ii) Study the variation of this inhibition according to the organ (i.e., leaf, stem bark and fruit) and the geographical origin (i.e., mountain and littoral) of the plant *P. lentiscus*. This metabolomic method was based on the link between phytochemical profiling by ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-ESI-HRMS) and α -glucosidase dosage data.

This study could contribute to the valorization of the antidiabetic potential of this resource in the pharmaceutical field through, for example, the elaboration of traditionally improved drugs (TID) in developing countries. The antidiabetic potential of this plant could also be exploited in the field of food supplements.

2. Materials and Methods

2.1. Chemicals

The main chemicals used for the measurements of α -glucosidase inhibition were α -glucosidase from *Bacillus stearothermophilus* (G3651-250 UN, 84 units/mg, 86% protein), p-nitrophenyl α -D-glucopyranoside (N1377, $\geq 99.0\%$) and acarbose (PHR1253-Pharmaceutical Secondary Standard; Certified Reference Material). The analytical standards for the UHPLC-ESI-HRMS analysis were (–)-epigallocatechin (EGC) ($\geq 90\%$, 08108-supeplo), myricitrin ($\geq 99.0\%$, 91255, Sigma-Aldrich, Saint Quentin Fallavier, France), apigenin 7-glucoside ($\geq 97.0\%$, 44692, Supelco) and tiliroside ($\geq 95.0\%$, PHL89809-phyproof® Reference Sub-

stance). These analytical-grade chemicals used were purchased from Supelco and Sigma-Aldrich, Saint Quentin Fallavier, France.

2.2. Plant Collection

The plant species *P. lentiscus* was identified using the flora of Quézel and Santa (1962–1963). In addition, the lentisk samples were deposited in the herbarium of the National Superior School of Agronomy of Algeria. This identification was confirmed by Benhouhou and resulted in the issuance of a certificate attesting that this plant was indeed *P. lentiscus*. The samples of leaves, stems and fruits of *P. lentiscus* were collected separately from plants in the Algerian region of Tizi-Ouzou. Its relatively contrasted climatic regimes are representative of those of the large area of northern Algeria between the littoral and mountains. For this study, we selected two geographical sites in the Tizi-Ouzou region: Ait-Irane on the mountain and Tizirt on the littoral. In all, 54 samples were collected. The information of the 54 samples, such as the collected site, collected date, GPS of each collection site and morphological variation in the characters of each sample, is provided in Table 1. The lentisk samples harvested from the two sites (mountain and littoral) do not show remarkable morphological differences according to the difference in altitude of the harvesting sites (Table 1).

Table 1. Information on lentisk samples harvested on the mountain and on the littoral.

| Sites | Collected Date | 54 Samples (9 Trees × 3 Organs × 2 Sites) | Morphological Variations | Longitude | Latitude | Altitude | Annual Temperature | |
|---------------------------------|---------------------|---|--------------------------------------|------------------|-----------------|----------|--------------------|----------------|
| Site 1 Ait-Irane Mountain | Mid-October 2019 | 9 lentisk trees (3 organs: leaves, stem bark and fruit) = 27 samples | Unremarkable for the same organ type | 36°29'58.3" N | 4°04'43.4" E | 876 m | Min 0.5 °C | Max 31.9 °C |
| Site 2 Tizirt Littoral | Mid-October 2019 | 9 lentisk trees (3 organs: leaves, stem bark and fruit) = 27 samples | Unremarkable for the same organ type | 36°53'43.0" N | 4°11'00.4" E | 13 m | Min 7.4 °C | Max 27.9 °C |

No site-specific morphological variations for the same organ type. More information on the climatic conditions at these two sites is presented in Tables S1 and S2.

The Mediterranean climate in Ait-Irane is characterized by a dry summer and relatively low temperatures during winter (Table S1). On the other hand, the summer and winter temperatures are less extreme, and the humidity is higher throughout the year in Tizirt (Table S2). At each site, a set of nine individual female trees was selected for all of the different samples. The collection was conducted at sunrise in autumn (6–8 a.m.) in October 2019.

2.3. Drying and Extraction

The samples from each organ were cleared of debris and air-dried in the dark for 7 days at 25–30 °C. The samples were ground using a ball mill. Fifty-four powdered samples were obtained (9arbusts*2sites*3organs). A methanol extraction of each powder (200 mg) from each organ was performed under heating at 70 °C for 30 min in an Eppendorf Thermo Mixer. The resulting mixture was centrifuged at 1100× *g* for 5 min. The recovered supernatant was evaporated under nitrogen. The dry crude extract recovered after the evaporation of methanol was dissolved in a 50:50 (*v/v*) water/cyclohexane mixture. After centrifugation, the aqueous phase was collected and lyophilized [49]. The lyophilized aqueous extract was stored at −20 °C for LC-MS analysis and biological activity evaluation.

2.4. UHPLC-ESI-HRMS Analysis of the Extracts

Each lyophilized aqueous extract (54 extracts) was dissolved in 2 mL of a 50:50 (*v/v*) water/methanol mixture. After shaking and sonication for one minute, the solutions were diluted to 1:10 in a 50:50 (*v/v*) water/methanol mixture for UHPLC-ESI-HRMS analysis. The UHPLC-ESI-HRMS analysis conditions were set according to Tchoumtchoua et al. (2019) [50], with some slight modifications.

The UHPLC-ESI-HRMS analyses were performed on an ACQUITY UPLC I-Class system coupled to a high-resolution hybrid Vion IMS QTOF (ion mobility quadrupole

time-of-flight) mass spectrometer equipped with an electrospray ionization (ESI) source (Waters, Manchester, UK). One microliter of each sample was injected, and the chromatographic separation was performed on a Kinetex Biphenyl column (100 × 2.1 mm, 1.7 μm) (Phenomenex, Torrance, CA, USA) maintained at 55 °C. The mobile phase flow rate was set at 0.5 mL/min, and a gradient elution from water with 0.1% formic acid (A) to methanol with 0.1% formic acid (B) was programmed as follows (A:B): 80:20 (t = 0 min), 80:20 (t = 0.5 min), 40:60 (t = 5 min), 10:90 (t = 6 min), 10:90 (t = 7 min), 80:20 (t = 7.5 min) and 80:20 (t = 10 min). The ESI source was set to a capillary voltage of 2.4 kV in the negative and positive ionization modes, with a sample cone voltage of 20 V. The source and desolvation temperatures were set to 120 and 450 °C, respectively. Nitrogen was used as the desolvation and cone gas at flow rates of 1000 and 50 L/h, respectively. For accurate mass measurements, lockmass correction was applied using the [M-H]⁻ ion at an *m/z* of 554.2615 from a solution of leu-enkephalin (100 pg/L in H₂O/CH₃CN (50:50, *v/v*) with 0.1% formic acid. The TOF was operated in the sensitivity mode, providing an average resolving power of 50,000 (FWHM). The HDMS^E spectra were recorded in the profile mode over a mass range of 50 to 2000 *m/z*, with the scan time set to 0.2 s. HDMS^E acquisition works by alternating two functions, a so-called LE (low-energy) one with a collision energy set at 6 eV to obtain non-fragmented spectra with information on precursor ions and a HE (high-energy) one with a ramp of collision energy values from 25 to 50 eV to obtain fragmented ion spectra thanks to an alignment by ion mobility of the fragments that had the same drift time as the precursors they came from. The analytical standards for the UHPLC-ESI-HRMS analysis were injected.

2.5. Glucosidase-Inhibitory Activity

The measurement of effect of the extract on the catalytic activity of α-glucosidase was performed according to the method of Bachhawat et al. (2011) [51], with a slight modification. In a 96-well plate, a reaction mixture containing 50 μL of phosphate buffer (50 mM, pH = 6.8), 10 μL of α-glucosidase (1 U/mL) (α-glucosidase from *Bacillus stearothermophilus*) and 20 μL of varying concentrations of extract (0, 2, 4, 6, 8 and 10 μg/mL) was preincubated at 37 °C for 15 min. Then, 20 μL of p-nitrophenyl α-D-glucopyranoside (PNPG) (1 mM) was added as a substrate, and the mixture was incubated again at 37 °C for 20 min. The reaction was stopped by adding 50 μL of sodium carbonate (0.1 M). The yellow color produced was read at 405 nm using a plate reader. Acarbose at various concentrations (0.2–1 mg/mL) was included as a positive control. A negative control without extracts was assayed in parallel. The experiment was performed three times for each sample. The UHPLC-ESI-HRMS injected standards were also tested for their effect on α-glucosidase inhibition. The results are expressed as percentages of inhibition, which were calculated according to the following formula (with A corresponding to the absorbance):

$$\text{Inhibition(\%)} = \frac{(A_{\text{negative control}} - A_{\text{sample}})}{A_{\text{negative control}}} \times 100$$

where $A_{\text{negative control}}$ corresponds to the absorbance of the control mixture (mixture with the buffer instead of the inhibitor), and A_{sample} represents the absorbance of the samples containing an inhibitor (extracts or acarbose). The α-glucosidase inhibitions of the standards injected for the UHPLC-ESI-HRMS analysis were also tested.

2.6. Metabolomic and Chemometric Analysis

Data processing was performed with the UNIFI software V1.9.4 (Waters, Manchester, UK). The multivariate matrix consisted of the ions detected in the samples after the UHPLC-QTOF-MS analysis in the negative (neg) and positive (pos) ionization modes (see Tables S3 and S4) in the retention time range (0.5–5 min). Only the ions with a response greater than 2000 (peak area) were retained in at least one condition (i.e., leaves, stem bark and fruit). Among these ions, those correlated with each other ($r \geq 0.80$) at the same retention time

were removed. Consensus orthogonal partial least squares (multiblock OPLS) was used as the chemometric tool to model the information in the rich chemical and biological data elaborated in this study [52]. This multiblock OPLS analysis was performed using the latest version of MATLAB 2020b. The UHPLC-QTOF-MS chromatograms in the negative and positive ion modes and the percentage of α -glucosidase inhibition were used for untargeted analysis. The multiblock OPLS showed the relationship between the responses (i.e., peak area) of the metabolites detected via the UHPLC-QTOF-MS chromatograms of the extracts analyzed and the intensity of the observed α -glucosidase inhibitory effect.

2.7. Intensity Variation of the Metabolites Identified

The objective of the univariate analysis was to study the variation of (i) the inhibition of the α -glucosidase enzyme and (ii) the intensity of the metabolites most likely responsible for this inhibition according to the part of the lentisk used and its geographical origin. These statistical analyses were performed by pairwise comparison through a post hoc Kruskal–Wallis test adjusted with Bonferroni correction using the package PMCMRplus version 1.9.4 [53] for analysis of the variances and the package MulticompView version 0.1–8 for analysis of the groups [54]. Significant differences were considered at the 95% confidence level. These analyses were performed with the R software version R ($\geq 3.5.0$).

3. Results

In the present work, the different aerial parts (i.e., leaves, stem barks and fruits) of the plant *P. lentiscus* were collected from two sites (i.e., mountain and littoral) in Tizi-Ouzou (Algeria). The 54 samples obtained were characterized phytochemically and biologically. Firstly, the evaluation of the α -glucosidase inhibition property in vitro of all of the extracts was performed. Secondly, metabolite profiling was performed using an up-to-date analytical technique: UHPLC-ESI-HRMS. Finally, a multivariate metabolomic analysis (multiblock OPLS) was performed in the following order:

- (i) Study of the α -glucosidase inhibition differences between the aerial parts and between the geographical origins of *P. lentiscus*;
- (ii) Characterization of the metabolites most involved in the inhibition of α -glucosidase.

3.1. α -Glucosidase-Inhibitory Activity

The inhibitory effect on α -glucosidase was estimated by evaluating the percentage of inhibition of this enzyme in a 96-well plate. Figure 1 presents the percentages of inhibition of α -glucosidase by the different lentisk extracts (i.e., leaves, stem barks and fruits at a concentration of 10 $\mu\text{g}/\text{mL}$) harvested from the two locations in Tizi-Ouzou (i.e., littoral and mountain). The stem bark extracts showed stronger inhibitory activity, and the average values were $84.7 \pm 5.9\%$ ($\text{IC}_{50} = 5.8 \pm 0.4$) and $69.9 \pm 19.9\%$ ($\text{IC}_{50} = 7.9 \pm 3.3$) at the littoral and mountain, respectively. The fruit extracts showed a lower effect ($13.6 \pm 6.2\%$) at both locations. The pairwise comparison through the Kruskal–Wallis test adjusted with Bonferroni correction [53,54] allowed for the study of the significance of the inhibition variation according to the organ and also the location. Depending on the location of the plant, the variation of the inhibitory effect was not significant for each type of organ. On the other hand, depending on the part of the plant used, the inhibition difference was significant between the stem barks and fruits and between the leaves and fruits.

We also tested acarbose (reference control; α -glucosidase inhibitor), a drug used for the treatment of type 2 diabetes. The inhibition by acarbose of α -glucosidase was approximately 100% (see Figure 1). Comparing the effect of the lentisk extracts with acarbose, we noticed that the inhibitory effects of acarbose and stem bark extracts on α -glucosidase were comparable. The difference between the two effects was not significant (p -value > 0.05) according to the Kruskal–Wallis test following pairwise comparisons using Dunn's many-to-one test [53]. This same test revealed that the difference in α -glucosidase inhibition was not significant between acarbose and leaf extracts, but it was significant

between acarbose and fruit extracts (p -value < 0.05). A figure showing the same results by an IC₅₀ calculation is included in the Supplementary Materials (Figure S1).




Figure 1. Boxplot showing α -glucosidase-inhibitory effect of lentisk leaves, stems barks and fruits from the mountain and littoral. (The means and medians are presented as black dots in the center of each box plot and by bars, respectively. The significance of the α -glucosidase inhibition variation is represented by letters (groups, a, b and ab) according to pairwise comparison through the Kruskal–Wallis test adjusted with Bonferroni correction).

3.2. Metabolomic and Chemometric Analysis

In order to objectively assess the differences in the α -glucosidase inhibition and chemical profile depending on the plant part and its geographical origin, the supervised approach, consensus orthogonal partial least squares (multiblock OPLS) based on UHPLC-ESI-HRMS profiling and in vitro enzyme inhibitory bioactivities, was performed. This chemometric approach also aimed to characterize the metabolites positively correlated with α -glucosidase inhibition.

The UHPLC-QTOF-MS data of 54 extracts were analyzed, and the values of the α -glucosidase-inhibitory activities were processed using multivariate data analysis (multiblock OPLS). The final matrix that was used for the multiblock OPLS analysis was composed of 198 ions in the negative ionization mode and 160 ions in the positive one. The quality parameters of the multiblock OPLS model ($R^2 = 0.74$ and $Q^2 = 0.72$) demonstrate the good fit of this model. The two ion blocks (i.e., negative ionization mode (neg) and positive ionization mode (pos)) contributed in the same way to the constitution of the multiblock OPLS model (see Figure S2). The multiblock OPLS analysis generated two graphs: a score plot (Figure 2A) and a loading plot (Figure 2B). The two components (i.e., predictive and orthogonal) of the score plot showed a total variance of 81.5%, with 75% for the predictive component and 6.5% for the orthogonal component. This score plot separated the 54 samples (i.e., leaves, stem barks and fruits) according to the part of the plant used and the sampling location (i.e., littoral or mountain) into six different groups. The loading plot shows the metabolites detected in these extracts. The inhibitory effect increases going to the right of the predictive component of the loading plot. Therefore, we were interested in identifying metabolites located on the right end of the loading plot, with coordinates greater than five on the predictive component (see the values of these coordinates in

Table S5 in the Supplementary Materials). These metabolites were the ones most involved in the inhibition of α -glucosidase in the different lentisk extracts (Figure 2B). These metabolites were present in intense concentrations in the stem barks (Figure 2A,B).




Figure 2. Multiblock OPLS analysis performed on the UHPLC-ESI-HRMS and α -glucosidase inhibition data: (A) score plot—lentisk samples: ■ Littoral/ Δ Mountain; (B) loading plot—metabolites detected: ■ ions with negative ionization/ Δ ions with positive ionization: metabolites; M1: epigallocatechin(4a->8)epigallocatechin (1); M2: 3,5-O-digalloylquinic acid; M3: (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (1); M4: epigallocatechin (4a->8)epigallocatechin (2); M5: (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (2); M6: dihydroxy benzoic acid pentoside.

The tentative Identification of the metabolites most positively correlated with α -glucosidase inhibition was based on UHPLC-QTOF-MS (RT, m/z , molecular formula) data. Using the characteristic fragments obtained after the HDMS^E analysis, we were able to propose fragmentation patterns identifying each molecule. The identification process was also based on comparisons using on the available databases, including the KnaPSack metabolome database, MassBank, Kyoto Encyclopedia of Genes and Genomes (KEGG) and MetFrag, as well as the UNIFI library. This identification was also confirmed using previous publications on the same molecules. Following this identification methodology, we identified four metabolites, shown in color in Figure 2B, in the negative and positive ionization modes and two other metabolites in the negative ionization mode.

3.3. UHPLC-ESI-HRMS Identification of α -Glucosidase Inhibitory Metabolites

The *P. lentiscus* extracts were found to have an α -glucosidase inhibition effect that was more or less impactful according to the plant's living environment (i.e., mountain or littoral) and the considered organ (i.e., leaves, stem barks or fruits). With the aim of obtaining a better understanding of this effect, UHPLC-ESI-HRMS analyses were performed to characterize the phytochemical content that could be responsible for α -glucosidase inhibition. Statistical analyses (i.e., multiblock OPLS) were used for comparing the data of the different extracts and to highlight those for which the metabolic content could be correlated with strong α -glucosidase inhibition activity. This approach led to a total of six compounds. These compounds were putatively identified as phenolic compounds by ESI-HRMS in the HDMS^E mode based on accurate mass measurements of the corre-

sponding ions and their fragments. The UHPLC-ESI-HRMS data results are summarized in Tables 2 and S5. Indeed, these tables include the retention time (RT), observed m/z , mass error value (ppm), molecular formula, characteristic fragment ions used for identification with their intensities and the suggested identity of each compound in agreement with previous studies. Table S5 in the Supplementary Materials contains more information than Table 2.

Table 2. Phenolic compounds identified in *P. lentiscus* extracts by UHPLC-ESI-HRMS in the negative mode. (The equivalent information for the positive mode is presented in Supplementary Materials Table S6).

| N° Metabolite | RT (min) | m/z (obs) [M-H] [−] | Error (ppm) | HDMS ^E Fragment Ions (Intensity, %) | Molecular Formula | Suggested Compound | Ref |
|---------------|----------|--------------------------------|-------------|--|---|--|---------|
| 1 | 0.45 | 609.1242 | −1.26 | 441.0825 (2.99), 423.0722 (100), 305.0667 (29.49), 261.0397 (15.71), 219.0659 (14.46), 177.0186 (26.94), 125.0241(18.09) | C ₃₀ H ₂₆ O ₁₄ | Epigallocatechin(4a>8)epigallocatechin | [55–57] |
| 2 | 0.55 | 495.0774 | −2.03 | 343.0661(100), 325.0550(15.74), 191.0551(87.47), 169.0136(37.71) | C ₂₁ H ₂₀ O ₁₄ | 3,5-O-Digalloylquinic acid | [43] |
| 3 | 0.56 | 761.1339 | −3.46 | 609.1228(12.42), 591.1134(5.98), 465.0820 (12.76), 423.0820(100), 305.0658(46.73) | C ₃₇ H ₃₀ O ₁₈ | (Epi)gallocatechin-3'-Ogalloyl-(epi)gallocatechin | [58] |
| 4 | 0.61 | 609.1233 | −1.51 | 423.0716 (100) | C ₃₀ H ₂₆ O ₁₄ | Epigallocatechin (4a->8)epigallocatechin (isomer) | [57–59] |
| 5 | 0.72 | 761.1344 | −2.28 | 423.0715 (100) | C ₃₇ H ₃₀ O ₁₈ | (Epi)gallocatechin-3'-Ogalloyl-(epi)gallocatechin (isomer) | [58] |
| 6 | 0.73 | 285.0608 | −2.76 | 108.0209 (100) | C ₁₂ H ₁₄ O ₈ | Dihydroxy benzoic acid pentoside | [60] |

According to these HDMS^E data, the six different metabolites have been widely identified as:

Epigallocatechin(4a->8)epigallocatechin, or a dimer of (epi)gallocatechin (2×EGC): The HDMS^E spectrum of metabolite 1 (RT 0.45 min) revealed a deprotonated pseudomolecular ion [M-H][−] at m/z 609.1242, allowing us to access the molecular formula C₃₀H₂₆O₁₄. All of the fragment ions obtained were found to be typical of the proanthocyanidin family. Heterocyclic ring fission (HRF), retro-Diels–Alder (RDA) and quinone-methide (QM) were the characteristic fragmentation mechanisms observed for this class of molecule. Indeed, RDA and HRF fragmentation provide information on bond hydroxylation following ring cleavage, while interflavan bond cleavage, also called quinone methide (QM) fragmentation, can reveal information on the nature of monomeric units. A proposed fragmentation pathway describing the formation of the characteristic fragment ions for this molecule is depicted in Figure 3. First, the fragmentation of the [M-H][−] ion at m/z 609.1242 occurred after a neutral loss of 168 Da to the low-intensity fragment ion at m/z 441.0825 by the RDA mechanism in the C ring. Thereafter, the loss of a water molecule (−18 Da) from the ion at m/z 441.0825 was observed to result in the ion at m/z 423.0722, which was the base peak in the spectrum. The fragment ion at m/z 305.0667 was obtained from m/z 609.1242 by an interflavan bond cleavage (QM) between the C and D rings, evidencing the nature of this compound as one composed of two units having the same mass, supporting the

hypothesis of a dimer of (epi)gallocatechin [56,61]. The presence of the fragment ion at m/z 125.0241 can be explained by the HRF mechanism from the corresponding ion of (epi)gallocatechin at m/z 305 releasing phloroglucinol from the A ring [62]. The other fragments detected at m/z 177, 219, 261 and 285 were characteristic ions produced from the fragmentation of m/z 305 [43,62]. It should be noted that epigallocatechine dimers composed of two (epi)gallocatechin units have been previously identified in grape canes and red wine [56,61,63] but never in *P. lentiscus* extracts so far.




Figure 3. Proposed fragmentation pathways for epigallocatechin(4a->8)epigallocatechin.

Epigallocatechin(4a->8)epigallocatechin (isomer of metabolite 1): Metabolite 4 (RT 0.61 min) was putatively identified by HDMS^E as an isomer of metabolite 1 (epigallocatechin(4a->8)epigallocatechin, a dimer of epigallocatechine), as the same molecular formula, $C_{30}H_{26}O_{14}$, was found from the corresponding $[M-H]^-$ ion at m/z 609.1233. Moreover, the same characteristic fragment at m/z 423.0716 was obtained from the precursor ion at m/z 609.1233 by the loss of an RDA fragment (-168 Da) followed by the loss of water (-18 Da) (Figure 3).

(Epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin: Metabolite 3 (RT 0.56 min), detected at m/z 761.1339 with the corresponding molecular formula $C_{37}H_{30}O_{18}$, was identified as (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin. Firstly, the fragmentation of the $[M-H]^-$ ion at m/z 761.1339 resulted in the fragment at m/z 609.1228 by the loss of 152 Da corresponding to a galloyl residue. For this last fragment ion, the molecular formula

$C_{30}H_{26}O_{14}$ was obtained, revealing that this metabolite could have an epigallocatechin dimer structure type. Indeed, the typical fragment ions at m/z 423.0820 and 305.0568, as previously described for epigallocatechin dimers, were observed. In addition, two other fragments were observed on the fragmented HDMS^E spectrum in agreement with the structure proposed for metabolite 3, namely, the ion at m/z 591.1134, which was produced by the loss of a water molecule (-18 Da) from the m/z 609.1228, and the ion at m/z 465.0820 obtained by the loss of a phloroglucinol (-126 Da) molecule at m/z 591.1134. The details of the fragmentation mechanism and of the characteristic fragmentation structures discussed above can be found in Figure 4a,b.




Figure 4. Cont.




Figure 4. (a) Fragmentation pathways of (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin showing the formation of the fragmentations at m/z 609.12, 591.11 and 465.08. (b) Fragmentation pathways of (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin showing the formation of the fragment ions at m/z 423.08 and 305.06.

From the preceding points, this compound was identified as (epi)gallocatechin-(4,8')-3'-O-galloyl-(epi)gallocatechin [58]. This compound has never been detected in *P. lentiscus* extracts before.

(Epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (isomer of metabolite 3): Metabolite 5 (RT 0.72 min) was putatively identified by HDMS^E as an isomer of metabolite 3 ((epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin), as the same molecular formula, C₃₇H₃₀O₁₈, was found from the corresponding [M-H]⁻ ion at m/z 761.1344. Moreover, the same characteristic fragment ion at m/z 423.0716 was obtained from the precursor ion at m/z 609.1233 by the loss of an RDA fragment (−168 Da) followed by the loss of water (−18 Da) (Figure 4b). All of these observations are in agreement with a structure that could be an isomer of (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin.

3,5-O-digalloylquinic acid: Metabolite 2 (RT 0.55 min) was putatively identified as 3,5-O-digalloylquinic acid. It was characterized by an [M-H]⁻ ion at m/z 495.0774, enabling us to find the molecular formula C₂₁H₂₀O₁₄. Under fragmented HDMS^E conditions, the [M-H]⁻ ion at m/z 495.0774 underwent two successive losses of a galloyl moiety (−152 Da), leading to fragment ions at m/z 343.0661 and 191.0551. The accurate mass measurement for the fragment at m/z 191.0551, with the determination of its molecular formula as C₇H₁₁O₆, confirmed the quinate structure, and for the fragment ion at m/z 169.0136 with the corresponding molecular formula C₇H₅O₅, a gallate structure was determined [42,43,64]. A proposed fragmentation pathway is described in Figure 5.




Figure 5. Fragmentation pathway of 3,5-O-digalloylquinic acid.

This compound, labeled metabolite 2, was recently identified in *P. lentiscus* leaves [43,64].

Dihydroxy benzoic acid pentoside: Metabolite 6 (RT 0.73 min) was characterized by an $[\text{M}-\text{H}]^-$ ion at m/z 285.0608, enabling us to find the molecular formula $\text{C}_{12}\text{H}_{14}\text{O}_8$ for this compound. Under fragmented HDMS^E conditions, the $[\text{M}-\text{H}]^-$ ion at m/z 285.0608 first underwent a loss of dehydrated pentose (-132 Da) to provide hydroxybenzoate, which was immediately followed by the loss of a radical species, CO_2H (-45 Da), leading to the radical anion at m/z 108.0209 [60]. All of the structures of the fragments and the losses are presented in Figure 6. Thus, metabolite 6 was putatively identified as dihydroxy benzoic acid pentoside.




Figure 6. Fragmentation pathways of dihydroxy benzoic acid pentoside.

3.4. Intensity Variation of the Metabolites Identified

The univariate analysis generated box plots of the metabolites identified (in negative ionization, Figure 7). Each box plot presents the contents of a metabolite in the different lentisk parts from the mountain and littoral. The metabolite intensities were expressed as the area of the chromatographic peak corresponding to each metabolite in the extracts. The different letters indicate that the intensities were significantly dissimilar after a post hoc Kruskal–Wallis test (p -value < 0.05) for each compound. This statistical test showed that the location of the plant had no significant effect on the variation of the intensity of the metabolites detected in the lentisk's different parts.




Figure 7. Box plots of the metabolite contents in different organs—leaves, stem barks and fruits—from the mountain and littoral. (The significance of the metabolite intensity variation is presented by letters (groups, a, b, c, ab, bc and abc) according to pairwise comparison through the Kruskal-Wallis test adjusted with Bonferroni correction).

According to the intensities of the identified metabolites (i.e., chromatographic peak areas), we can say that the samples from the littoral had higher concentrations of α -glucosidase-inhibitory compounds, especially the stem barks. These results are consistent with those of the multiblock OPLS analysis.

4. Discussion

In the present work, *P. lentiscus* was studied for its use as a hypoglycemic agent in traditional medicine. This is the first study that reports the phytochemical screening of α -glucosidase-inhibiting compounds. These compounds were present in the different parts of *P. lentiscus* harvested in two different regions. The work was based on a chemometric study that linked biologic activity to data from a UHPLC-ESI-HRMS analysis.

Our results show the variability of the inhibition of α -glucosidase in regards to the organ and the geographical origin of Algerian lentisk. The α -glucosidase inhibition of lentisk stem bark was measured in this study. Compared to the previous studies in the literature, the fruit extracts (IC₅₀ = 42 μ g/mL) showed a greater inhibitory potency than did Sardinian *P. lentiscus* fruit aqueous extracts, with IC₅₀ = 230 μ g/mL [30]. The inhibition percentages of α -glucosidase of the leaves and fruit extracts (49% and 13%, respectively) were comparable to the inhibition percentages of α -amylase of ethanolic leaf (55%) and fruit (54%) extracts [23]. The activity of α -glucosidase inhibition has been tested in several other plants [65–67]. Plant extracts including *Tamarix nilotica* (IC₅₀ = 33.3 μ g/mL) [65], *Tetracera scandens* (IC₅₀ = 3.4 μ g/mL) [66] and *Cosmos caudatus* (IC₅₀ = 39.1 μ g/mL) [67] have shown promising α -glucosidase inhibition. These activities are comparable to those of acarbose and to the results found in the present study. In our case, the geographical origin did not have a significant effect on the variation of the α -glucosidase inhibition. A previous study revealed that *Parkia speciosa* pods collected from different locations in Malaysia show different levels of α -glucosidase-inhibitory activity [68]. Our results indicate that the change in the α -glucosidase inhibition activity was more significant according to the part of the plant than its habitat. This is explained by the variation in the chemical compositions of the different extracts. Multivariate models can show the predictive power of metabolomic analysis for α -glucosidase inhibition and can indicate which groups of metabolites contribute most to this activity [24,25]. Therefore, the metabolomic approach applied in our study allowed us to characterize the metabolites that contributed more to the inhibition of α -glucosidase enzymatic activity. A total of six compounds were identified, of which four were flavonoids derived from epigallocatechin. To the best of our knowledge, epigallocatechin(4a→8)epigallocatechin (two isomers), (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (two isomers) and dihydroxy benzoic acid pentoside, but not 3,5-O-digalloylquinic acid, were identified in the different extracts (i.e., leaves, stem barks and fruits) of *P. lentiscus*. The monomer epigallocatechin, the basic structure of four molecules among these metabolites, has been identified previously in lentisk leaves [19,64]. Epigallocatechin, analyzed by UHPLC-ESI-HRMS as a standard, was detected even in our lentisk extracts. In addition, this compound had a better α -glucosidase-inhibitory activity (81.7%) compared to the other standards tested. Therefore, it is quite coherent that the metabolites derived from epigallocatechin (M1, M3, M4 and M5) contribute to the inhibition of α -glucosidase. Previous work has established statistical models of the relationship between the phytochemical profiles obtained via LC-MS/MS and the inhibition of α -glucosidase by plant extracts [66,67,69]. The results of this work revealed that α -glucosidase-inhibitory activity was probably due to the presence of terpenoids, fatty acids, phenolic, flavonoids (epigallocatechin-3-O-gallate) and flavonoid glycosides (quercetin 3-O-glucoside) [65,67]. (-)-Epigallocatechin-3-O-gallate offers a promising hypoglycemic effect [65,70].

Most of these metabolites, especially epigallocatechin derivatives, have been reported for their ability to inhibit α -glucosidase, isolated from other plants [24,26]. Flavanol compounds (i.e., epigallocatechin, epigallocatechin gallate isomers, asinensin A, aflavin-3-gallate isomers, gallocatechin-(4 α →8)-epigallocatechin and herbacetin) identified in

P. speciosa most likely have a major role in α -glucosidase-inhibitory activity [68]. Previous studies determined several key structural features needed for monomeric flavonoids to inhibit α -glucosidase activity [71–73]. The compounds derived from epigallocatechin (i.e., epigallocatechin-(4 α →8)-epigallocatechin (two isomers) and(epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (two isomers)) and identified in *P. lentiscus* have been described as having a major role in α -glucosidase-inhibitory activity because of the structural configuration of the double bonds conjugated to the 4-oxo and hydroxyl groups [73]. In addition, the presence of an esterified gallate group at the 3 position of the C ring has been suggested to be critical for the interaction of flavan-3-ols with the α -glucosidase enzyme [71,72]; this is the case for the molecule (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin. In addition, the substitution of sugar units or a hydroxyl group by a galloyl increases the efficacy of flavonoids against α -glucosidase [74]. The molecule 3,5-O-digalloylquinic acid probably has an important role in the inhibition of α -glucosidase. An ethnomedicinal study carried out on the hypoglycemic effects of medicinal plants showed that the leaves and fruits of *Arbutus unedo*, an antidiabetic medicinal plant, are rich in galloyl quinic acid [18]. A study by Quaresma et al.(2020) [75] reported that dihydroxy pentoside acid is among the phenolic compounds that can influence the inhibition of the active site of enzymes [75]. In this study, the butanol fraction of *Banisteriopsis argyrophylla* leaves rich in dihydroxy pentoside acid showed good inhibitory activity of α -glucosidase.

Examining the literature, in terms of lentisk phytochemistry composition, the leaf is the most studied. Shikimic acid [43], myricetin and its derivatives, including myricetin galactosides, as well as quercetin and its derivatives, were detected [64]. Luteolin-7-O-glycuronide, luteolin-3-O-rutinoside and kaempferol-3-O-di-hexose-O-pentose [19] were identified in the methanolic extracts. Other researchers have reported the presence of pentoside derivatives including quercetin-O-galloylpentoside in hydromethanolic leaf extracts [43]. Phenolic acids including gallic acid, 3-galloyl quinic acid, 5-galloyl quinic acid, 3,5-di-O-galloyl quinic acid and 1,5-di-O-galloyl quinic acid were detected in the aqueous extracts of leaves and fruits [30]. A digalloylquinic acid derivative was detected in the lentisk fruit and stem [22]. Catechin was the most representative flavanol in *P. lentiscus* leaves [23,76], while procyanidin B1 was the most abundant flavanol in the fruit extracts [77].The study conducted by Aissat et al. (2022) [78] resulted in the identification of seven flavanols, such as procyanidin B1 and B3, epigallocatechin gallate and gallocatechin and epicatechin gallate, in five different physiological stages of lentisk fruit from Algeria. There is only one study describing the phytochemical profile of the whole stem [22]. Therefore, our study is the first report on the phytochemical composition of lentisk stem barks.

Studies have shown that a plant's geographical location has a significant influence on the composition and content of secondary metabolites [48,68]. According to the boxplots presented in Figure 7, the intensity of the identified metabolites was relatively stable (letters a, b, ab) according to the geographical origin (i.e., littoral and mountain). The slight variations were due to the many climatic and abiotic factors which can affect the biosynthesis of secondary metabolites in plants [68,79]. Colder temperatures at higher altitudes (mountains) can cause overproduction of phytochemicals [79]. Previous research has suggested that increasing altitude and consequent changes in solar radiation and temperature in plant habitats (as in Tables S1 and S2) may be strongly correlated with the contents of secondary metabolites, especially phenolics, due to their defensive function against oxidative damage [79]. On the other hand, the variation in the contents of metabolites (α -glucosidase inhibitors) depending on the part of the *P. lentiscus* plant used was more significant. The plant part plays a key role in the variation of the chemical composition of the plant extract [22]. The stem barks were characterized by an abundance of these α -glucosidase inhibitors compared to the other lentisk organs (i.e., leaves and fruits) at both sites (i.e., littoral and mountain). The results of this study suggest that lentisk stem bark from the littoral area is a good source of α -glucosidase inhibitors.

5. Conclusions

The results of this work revealed that the stem bark and leaves from *P. lentiscus* harvested from different areas of Algeria presented a significant activity of α -glucosidase inhibition. The stem barks harvested at the littoral had the highest inhibitory activity toward α -glucosidase. This activity was comparable to that of acarbose. A multi-block OPLS analysis was used to define the molecules that exhibited α -glucosidase inhibitory effects. The UHPLC-ESI-HRMS analysis enabled the identification of six metabolites: epigallocatechin(4a->8)-epigallocatechin (two isomers), (epi)gallocatechin-3'-O-galloyl-(epi)gallocatechin (two isomers), 3,5-O-digalloylquinic acid and dihydroxy benzoic acid pentoside. The intensities of these metabolites varied depending on the lentisk organ and habitat. The results of our study justify scientifically and consolidate the ethnopharmacological reports on the traditional use of lentisk leaves for the treatment of type 2 diabetes. According to these results, the use of stem barks could be better adapted to the treatment of type 2 diabetes by traditional means—for example, the elaboration of traditionally improved drugs (TID) in developing countries. The antidiabetic potential of this plant could also be exploited in the field of food supplements.

Further studies on the identification of other active metabolites and their synergistic effects on α -glucosidase-inhibitory activity are still needed.

It is also important to consider preclinical and clinical trials of these lentisk extracts to determine their mechanisms of inhibition, their pharmacokinetics and their toxicology. Our results on the antidiabetic activity carried out *in vitro* show that the variation was quite stable according to the habitat. The same was true for the intensity variation of the metabolites that contributed most to this activity. Therefore, it would be interesting to extend the sampling to several geographical sites to better evaluate the antidiabetic activity and phytochemistry of lentisk as they relate to the environmental conditions of its habitat.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/metabo13020275/s1>, Figure S1: Boxplot showing the α -glucosidase-inhibitory effect of lentisk leaves, stems barks and fruits from the mountain and littoral; Figure S2: Contribution of the two blocks (neg and pos) to the constitution of the OPLS model; Table S1: Weather data collected between 1999 and 2019 in Ait-Irane, Algeria; Table S2: Weather data collected between 1999 and 2019 in Tizirt, Algeria; Table S3: Metabolomic data (OPLS, matrix-negative ionization); Table S4: Metabolomic data (OPLS, matrix-positive ionization); Table S5: UHPLC-ESI-HRMS data results and OPLS coordinates; Table S6: Phenolic compounds identified in *P. lentiscus* extracts by UHPLC-ESI-HRMS in the positive mode.

Author Contributions: Conceptualization, C.S. and R.M.; methodology, C.S. and R.M.; software, J.-X.F., C.S. and R.M.; validation, R.M., D.M., J.-X.F., N.J., F.A., F.F. and E.G.; formal analysis, C.S., R.M. and J.-X.F.; investigation, C.S., R.M., J.-X.F. and D.M.; resources, C.S., E.G. and F.F.; data curation, C.S., R.M., J.-X.F. and D.M.; writing—original draft preparation, C.S., R.M., D.M., J.-X.F., F.F., N.J., E.G. and F.A.; visualization, C.S., R.M., D.M., J.-X.F., F.F., N.J., E.G. and F.A.; supervision, E.G., F.F. and N.J.; project administration, C.S., E.G., F.F. and N.J.; funding acquisition, C.S., E.G., F.F., R.M. and D.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by (1) the French Ministry of Foreign Affairs through Campus France (No.973496A); (2) the “Conseil Régional de Picardie” through the MTV (Métabo-Typage Végétal) project; (3) the University of Picardie Jules Verne through the French Ministry of Higher Education and Research; the region “Hauts de France”; and the European FEDER fund within the so-called CPER programs devoted to equipment acquisitions. This work was also funded by Algerian authorities through the financial support of the Tizi-Ouzou UMMTO University and a social grant attributed to Chabha Sehaki for her PhD.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article or the Supplementary Materials.

Acknowledgments: The authors thank Salima Benhouhou (Ecole Nationale Supérieure Agronomique, ENSA, Algiers, Algeria) for the identification of the *P. lentiscus* plants, the recording of samples and the delivery of a certificate.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Benalla, W.; Bellahcen, S.; Bnouham, M. Antidiabetic medicinal plants as a source of alpha glucosidase inhibitors. *Curr. Diabetes Rev.* **2010**, *6*, 247–254. [[CrossRef](#)] [[PubMed](#)]
2. Tundis, R.; Loizzo, M.R.; Menichini, F. Natural products as α -amylase and α -glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: An update. *Mini Rev. Med. Chem.* **2010**, *10*, 315–331. [[CrossRef](#)] [[PubMed](#)]
3. Rees, D.A.; Alcolado, J.C. Animal models of diabetes mellitus. *Diabet. Med.* **2005**, *22*, 359–370. [[CrossRef](#)]
4. Sudesna, C.; Khunti, K.; Davies, M.J. Type 2 diabetes. *Lancet* **2017**, *389*, 2239–2251.
5. Vinholes, J.; Vizzotto, M. Synergisms in alpha-glucosidase inhibition and antioxidant activity of camellia sinensis l. kuntze and *Eugeniauniflora* L. ethanolic extracts. *Pharmacogn. Res.* **2017**, *9*, 101. [[CrossRef](#)]
6. Hedrington, M.S.; Davis, S.N. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. *Expert Opin. Pharmacother.* **2019**, *20*, 2229–2235. [[CrossRef](#)]
7. Nakhhae, A.; Sanjari, M. Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman. *J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci.* **2013**, *18*, 391.
8. Kast, R. Acarbose related diarrhea: Increased butyrate upregulates prostaglandin. *E. Inflamm. Res.* **2002**, *51*, 117–118. [[CrossRef](#)]
9. Apostolidis, E.; Kwon, Y.I.; Shetty, K. Inhibitory potential of herb, fruit, and fungal-enriched cheese against key enzymes linked to type 2 diabetes and hypertension. *Innov. Food Sci. Emerg. Technol.* **2007**, *8*, 46–54. [[CrossRef](#)]
10. Andrade, R.J.; Lucena, M.; Vega, J.L.; Torres, M. Acarbose-associated hepatotoxicity. *Diabetes Care* **1998**, *21*, 2029. [[CrossRef](#)]
11. Fujimoto, Y.; Ohhira, M.; Miyokawa, N.; Kitamori, S.; Kohgo, Y. Acarbose- induced hepatic injury. *Lancet* **1998**, *351*, 340. [[CrossRef](#)] [[PubMed](#)]
12. Gentile, S.; Turco, S.; Guarino, G.; Sasso, F.C.; Torella, R. Aminotransferase activity and acarbose treatment in patients with type 2 diabetes. *Diabetes Care* **1999**, *22*, 1217. [[CrossRef](#)] [[PubMed](#)]
13. Tattini, M.; Remorini, D.; Pinelli, P.; Agati, G.; Saracini, E.; Traversi, M.L.; Massai, R. Morpho-anatomical, physiological and biochemical adjustments in response to root zone salinity stress and high solar radiation in two Mediterranean evergreen shrubs, *Myrtuscommunis* and *Pistacia lentiscus*. *New Phytol.* **2006**, *170*, 779–794. [[CrossRef](#)] [[PubMed](#)]
14. Trabelsi, H.; Renaud, J.; Herchi, W.; Boukhchina, S.; Mayer, P. Triacylglycerols and aliphatic alcohols from fruits of three Tunisian *Pistacia lentiscus* populations. *J. Sci. Food Agric.* **2015**, *95*, 2028–2032. [[CrossRef](#)] [[PubMed](#)]
15. Nabila, B.; Fawzia, A.B.; Tatjana, K.P. Antioxidant and antimicrobial activities of the *Pistacia lentiscus* and *Pistacia atlantica* extracts. *Afr. J. Pharm. Pharmacol.* **2008**, *2*, 22–28.
16. Boudieb, K.; Kaki, S.A.S.A.; Amellal-Chibane, H. Traditional uses, phytochemical study and morphological characterization of *Pistacia lentiscus* L. fruits from three areas of northern Algeria. *J. Appl. Biosci.* **2019**, *135*, 13788–13797. [[CrossRef](#)]
17. Saïah, H.; Allem, R.; Kebir, F.Z.R. Antioxidant and antibacterial activities of six Algerian medicinal plants. *Int. J. Pharm. Pharm. Sci.* **2016**, *8*, 367–374.
18. Bouyahya, A.; El Omari, N.; Elmenyiy, N.; Guaouguaou, F.E.; Balahbib, A.; Belmehdi, O.; Salhi, N.; Imtara, H.; Mrabti, H.N.; El-Shazly, M.; et al. Moroccan antidiabetic medicinal plants: Ethnobotanical studies, phytochemical bioactive compounds, preclinical investigations, toxicological validations and clinical evidences; challenges, guidance and perspectives for future management of diabetes worldwide. *Trends Food Sci. Technol.* **2021**, *115*, 147–254.
19. El Bishbishy, M.H.; Gad, H.A.; Aborehab, N.M. Chemiometric discrimination of three *Pistacia* species via their metabolic profiling and their possible in vitro effects on memory functions. *J. Pharm. Biomed. Anal.* **2020**, *177*, 112840. [[CrossRef](#)]
20. Umadevi, I.; Daniel, M.; Sabnis, S.D. Chemotaxonomic studies on some members of Anacardiaceae. *Proc. Plant Sci.* **1988**, *98*, 205–208. [[CrossRef](#)]
21. Romani, A.; Pinelli, P.; Galardi, C.; Mulinacci, N.; Tattini, M. Identification and quantification of galloyl derivatives, flavonoid glycosides and anthocyanins in leaves of *Pistacia lentiscus* L. *Phytochem. Anal. Int. J. Plant Chem. Biochem. Tech.* **2002**, *13*, 79–86. [[CrossRef](#)] [[PubMed](#)]
22. Yemmen, M.; Landolsi, A.; Hamida, J.B.; Mégraud, F.; Ayadi, M.T. Antioxidant activities, anticancer activity and polyphenolics profile, of leaf, fruit and stem extracts of *Pistacia lentiscus* from Tunisia. *Cell. Mol. Biol.* **2017**, *63*, 87–95. [[CrossRef](#)] [[PubMed](#)]
23. Mehenni, C.; Atmani-Kilani, D.; Dumarçay, S.; Perrin, D.; Gérardin, P.; Atmani, D. Hepatoprotective and antidiabetic effects of *Pistacia lentiscus* leaf and fruit extracts. *J. Food Drug Anal.* **2016**, *24*, 653–669. [[CrossRef](#)] [[PubMed](#)]
24. Trifan, A.; Zengin, G.; Sinan, K.I.; Wolfram, E.; Skalicka-Woźniak, K.; Luca, S.V. LC-HRMS/MS phytochemical profiling of *Symphytumofficinale* L. and *Anchusaachroleuca* M. Bieb. (Boraginaceae): Unveiling their multi-biological potential via an integrated approach. *J. Pharm. Biomed. Anal.* **2021**, *204*, 114283. [[CrossRef](#)] [[PubMed](#)]

25. Rocchetti, G.; Miras-Moreno, M.B.; Zengin, G.; Senkardes, I.; Sadeer, N.B.; Mahomoodally, M.F.; Lucini, L. UHPLC-QTOF-MS phytochemical profiling and in vitro biological properties of *Rhamnuspetiolaris* (Rhamnaceae). *Ind. Crops Prod.* **2019**, *142*, 111856. [[CrossRef](#)]
26. Farag, M.A.; Sakna, S.T.; El-Fiky, N.M.; Shabana, M.M.; Wessjohann, L.A. Phytochemical, antioxidant and antidiabetic evaluation of eight *Bauhinia* L. species from Egypt using UHPLC-PDA-qTOF-MS and chemometrics. *Phytochemistry* **2015**, *119*, 41–50. [[CrossRef](#)] [[PubMed](#)]
27. Syabana, M.A.; Yuliana, N.D.; Batubara, I.; Fardiaz, D. α -glucosidase inhibitors from *Syzygiumpolyanthum* (Wight) Walp leaves as revealed by metabolomics and in silico approaches. *J. Ethnopharmacol.* **2022**, *282*, 114618. [[CrossRef](#)] [[PubMed](#)]
28. Assefa, S.T.; Yang, E.Y.; Asamenew, G.; Kim, H.W.; Cho, M.C.; Lee, J. Identification of α -Glucosidase Inhibitors from Leaf Extract of Pepper (*Capsicum* spp.) through Metabolomic Analysis. *Metabolites* **2021**, *11*, 649. [[CrossRef](#)] [[PubMed](#)]
29. Sehaki, C.; Jullian, N.; Ayati, F.; Fernane, F.; Gontier, E. A Review of *Pistacia lentiscus* Polyphenols: Chemical Diversity and Pharmacological Activities. *Plants* **2023**, *12*, 1–20. [[CrossRef](#)] [[PubMed](#)]
30. Foddai, M.; Kasabri, V.; Afifi, F.U.; Azara, E.; Petretto, G.L.; Pintore, G. In vitro inhibitory effects of Sardinian *Pistacia lentiscus* L. and *Pistacia terebinthus* L. on metabolic enzymes: Pancreatic lipase, α -amylase, and α -glucosidase. *Starch-Stärke* **2015**, *67*, 204–212. [[CrossRef](#)]
31. Benhammou, N.; Bekkara, F.A.; Panovska, T.K. Antiradical capacity of the phenolic compounds of *Pistacia lentiscus* L. and *Pistacia atlanticadesf.* *Adv. Food Sci.* **2007**, *29*, 155–161.
32. Ghenima, A.I.; Idir, M.; Nadjet, M.G.; Samia, M.A.; Mihoub, Z.M.; Karim, H. In vitro evaluation of biological activities of *Pistacia lentiscus* aqueous extract. *Int. J. Pharm. Pharm. Sci.* **2015**, *7*, 133–139.
33. Amessis-Ouchemoukh, N.; Madani, K.; Falé, P.L.; Serralheiro, M.L.; Araújo, M.E.M. Antioxidant capacity and phenolic contents of some Mediterranean medicinal plants and their potential role in the inhibition of cyclooxygenase-1 and acetylcholinesterase activities. *Ind. Crops Prod.* **2014**, *53*, 6–15. [[CrossRef](#)]
34. Belhachat, D.; Aid, F.; Mekimene, L.; Belhachat, M. Phytochemical screening and in vitro antioxidant activity of *Pistacia lentiscus* berries ethanolic extract growing in Algeria. *Mediterr. J. Nutr. Metab.* **2017**, *10*, 273–285. [[CrossRef](#)]
35. Salhi, A.; Bellaouchi, R.; El Barkany, S.; Rokni, Y.; Bouyanzer, A.; Asehraou, A.; Amhamdi, H.; Hammouti, B. Total phenolic content, antioxidant and antimicrobial activities of extracts from *Pistacia lentiscus* leaves. *Casp. J. Environ. Sci.* **2019**, *17*, 189–198.
36. Remila, S.; Atmani-Kilani, D.; Delemasure, S.; Connat, J.L.; Azib, L.; Richard, T.; Atmani, D. Antioxidant, cytoprotective, anti-inflammatory and anticancer activities of *Pistacia lentiscus* (Anacardiaceae) leaf and fruit extracts. *Eur. J. Integr. Med.* **2015**, *7*, 274–286. [[CrossRef](#)]
37. Azib, L.; Debbache-Benaida, N.; Da Costa, G.; Atmani-Kilani, D.; Saidene, N.; Ayouni, K.; Richard, T.; Atmani, D. *Pistacia lentiscus* L. leaves extract and its major phenolic compounds reverse aluminium-induced neurotoxicity in mice. *Ind. Crops Prod.* **2019**, *137*, 576–584. [[CrossRef](#)]
38. Bakli, S.; Daoud, H.; Amina, Z.; Nouari, S.; Asma, B.; Soufiane, G.; Oumaima, N. Antimicrobial and Antioxidant Activities of Flavonoids Extracted from *Pistacia lentiscus* L., Leaves. *J. Drug Deliv. Ther.* **2020**, *10*, 83–89. [[CrossRef](#)]
39. Iauk, L.; Ragusa, S.; Rapisarda, A.; Franco, S.; Nicolosi, V.M. In vitro antimicrobial activity of *Pistacia lentiscus* L. extracts: Preliminary report. *J. Chemother.* **1996**, *8*, 207–209. [[CrossRef](#)]
40. Alhadad, A.O.; Salem, G.S.; Elmhdwi, M.F.; Hussein, S.M.; Elshareef, S.M. Assessments of Antibacterial and Antioxidant Properties in the Methanolic and Aqueous Leaf Extracts of *Pistacia lentiscus* against Different Antibiotic Resistance Pathogenic Bacteria. *Adv. Biosci. Biotechnol.* **2022**, *13*, 113–133. [[CrossRef](#)]
41. Mansour-Djaalab, H.; Kahlouche-Riachi, F.; Djerrou, Z.; Serakta-Delmi, M.; Hamimed, S.; Trifa, W.; Djaalab, I.; HamdiPacha, Y. In vitro evaluation of antifungal effects of *Lawsoniainermis*, *Pistacia lentiscus* and *Juglans regia*. *Int. J. Med. Aromat. Plants* **2012**, *2*, 263–268.
42. Kirolos, F.N.; Elhawary, S.S.; Salama, O.M.; Elkhawas, Y.A. LC-ESI-MS/MS and cytotoxic activity of three *Pistacia* species. *Nat. Prod. Res.* **2019**, *33*, 1747–1750. [[CrossRef](#)]
43. Pacifico, S.; Piccolella, S.; Marciano, S.; Galasso, S.; Nocera, P.; Piscopo, V.; Fiorentino, A.; Monaco, P. LC-MS/MS profiling of a mastic leaf phenol enriched extract and its effects on H₂O₂ and A β (25–35) oxidative injury in SK-B-NE (C)-2 cells. *J. Agric. Food Chem.* **2014**, *62*, 11957–11966. [[CrossRef](#)] [[PubMed](#)]
44. Siano, F.; Cutignano, A.; Moccia, S.; Russo, G.L.; Volpe, M.G.; Picariello, G. (Phytochemical characterization and effects on cell proliferation of lentisk (*Pistacia lentiscus*) berry oil: A revalued source of phenolic. *Plant Foods Hum. Nutr.* **2020**, *75*, 487–494. [[CrossRef](#)] [[PubMed](#)]
45. Bouriche, H.; Saidi, A.; Ferradji, A.; Belambri, S.A.; Senator, A. Anti-inflammatory and immunomodulatory properties of *Pistacia lentiscus* extracts. *J. Appl. Pharm. Sci.* **2016**, *6*, 140–146. [[CrossRef](#)]
46. Bouriche, H.; Khalfaoui, S.; Meziti, H.; Senator, A. Anti-inflammatory activity of acetonic extract of *Pistacia lentiscus* fruits. *TOJSAT* **2013**, *3*, 40–48.
47. Dellai, A.; Souissi, H.; Borgi, W.; Bouraoui, A.; Chouchane, N. Antiinflammatory and antiulcerogenic activities of *Pistacia lentiscus* L. leaves extracts. *Ind. Crops Prod.* **2013**, *49*, 879–882. [[CrossRef](#)]
48. Parizad, S.; Dizadji, A.; Habibi, M.K.; Winter, S.; Kalantari, S.; Movi, S.; Tendero, K.L.; Alonso, G.; Moratalla-Lopez, N. The effects of geographical origin and virus infection on the saffron (*Crocus sativus* L.) quality. *Food Chem.* **2019**, *295*, 387–394. [[CrossRef](#)] [[PubMed](#)]
49. Nguyen, T.K.; Jamali, A.; Grand, E.; Morreel, K.; Marcelo, P.; Gontier, E.; Dauwe, R. Phenylpropanoid profiling reveals a class of hydroxycinnamoylglucaric acid conjugates in *Isatis tinctoria* leaves. *Phytochemistry* **2017**, *144*, 127–140. [[CrossRef](#)]

50. Tchoumtchoua, J.; Mathiron, D.; Pontarin, N.; Gagneul, D.; Van Bohemen, A.I.; OtogoN’Nang, E.; Mesnard, F.; Petit, E.; Fontaine, J.X.; Roland, M.; et al. Phenolic profiling of flax highlights contrasting patterns in winter and spring varieties. *Molecules* **2019**, *24*, 4303. [CrossRef]
51. Bachhawat, J.A.; Shihabudeen, M.S.; Thirumurugan, K. Screening of fifteen Indian ayurvedic plants for alpha-glucosidase inhibitory activity and enzyme kinetics. *Int. J. Pharm. Pharm. Sci.* **2011**, *3*, 267–274.
52. Boccard, J.; Rutledge, D.N. A consensus orthogonal partial least squares discriminant analysis (OPLS-DA) strategy for multiblock Omics data fusion. *Anal. Acta* **2013**, *769*, 30–39. [CrossRef] [PubMed]
53. Thorsten, P. Calculate Pairwise Multiple Comparisons of Mean Rank Sums. R Package Version PMCMRplus 1.9.4. 2021. Available online: <https://cran.r-project.org/web/packages/PMCMRplus/index.html> (accessed on 1 February 2022).
54. Graves, S.; Piepho, H.P.; Selzer, M.L. Package ‘multcompView’. *Vis. Paired Comp.* **2015**. Available online: <https://cran.stat.unipd.it/web/packages/multcompView/multcompView.pdf> (accessed on 1 February 2022).
55. Singh, A.; Kumar, S.; Kumar, B. LC-MS Identification of Proanthocyanidins in Bark and Fruit of six Terminalia species. *Nat. Prod. Commun.* **2018**, *13*, 555–560. [CrossRef]
56. Escobar-Avello, D.; Lozano-Castellón, J.; Mardones, C.; Pérez, A.J.; Saéz, V.; Riquelme, S.; Von Bear, D.; Vallverdú-Queralt, A. Phenolic profile of grape canes: Novel compounds identified by LC-ESI-LTQ-Orbitrap-MS. *Molecules* **2019**, *24*, 3763.
57. Abu-Reidah, I.M.; del Mar Contreras, M.; Arráez-Román, D.; Fernández-Gutiérrez, A.; Segura-Carretero, A. UHPLC-ESI-QTOF-MS-based metabolic profiling of *Vicia faba* L. (Fabaceae) seeds as a key strategy for characterization in foodomics. *Electrophoresis* **2014**, *35*, 1571–1581. [CrossRef]
58. Jaiswal, R.; Jayasinghe, L.; Kuhnert, N. Identification and characterization of proanthocyanidins of 16 members of the Rhododendron genus (Ericaceae) by tandem LC-MS. *J. Mass Spectrom.* **2012**, *47*, 502–515. [CrossRef]
59. D’Urso, G.; Montoro, P.; Piacente, S. Detection and comparison of phenolic compounds in different extracts of black currant leaves by liquid chromatography coupled with high-resolution ESI-LTQ-Orbitrap MS and high-sensitivity ESI-Qtrap MS. *J. Pharm. Biomed. Anal.* **2020**, *179*, 112926. [CrossRef]
60. Russo, D.; Kenny, O.; Smyth, T.J.; Milella, L.; Hossain, M.B.; Diop, M.S.; Rai, D.K.; Brunton, N.P. Profiling of phytochemicals in tissues from *Sclerocaryabirrea* by HPLC-MS and their link with antioxidant activity. *Int. Sch. Res. Not.* **2013**, *2013*, 10.
61. Teixeira, N.; Azevedo, J.; Mateus, N.; de Freitas, V. Proanthocyanidin screening by LC-ESI-MS of Portuguese red wines made with teinturier grapes. *Food Chem.* **2016**, *190*, 300–307. [CrossRef]
62. Miketova, P.; Schram, K.H.; Whitney, J.; Li, M.; Huang, R.; Kerns, E.; Valcic, S.; Timmermann, B.N.; Rourick, R.; Klohr, S. Tandem mass spectrometry studies of green tea catechins. Identification of three minor components in the polyphenolic extract of green tea. *J. Mass Spectrom.* **2000**, *35*, 860–869. [CrossRef]
63. Delcambre, A.; André, Y.; Saucier, C. Sequencing of red wine proanthocyanidins by UHPLC-ESI-QToF. *J. Appl. Bioanal.* **2015**, *1*, 46–54. [CrossRef]
64. Rodríguez-Pérez, C.; Quirantes-Piné, R.; Amessis-Ouchemoukh, N.; Madani, K.; Segura-Carretero, A.; Fernández-Gutiérrez, A. A metabolite-profiling approach allows the identification of new compounds from *Pistacia lentiscus* leaves. *J. Pharm. Biomed. Anal.* **2013**, *77*, 167–174. [CrossRef] [PubMed]
65. Daou, M.; Elnaker, N.A.; Ochsenkühn, M.A.; Amin, S.A.; Yousef, A.F.; Yousef, L.F. In vitro α -glucosidase inhibitory activity of *Tamarix nilotica* shoot extracts and fractions. *PLoS ONE.* **2022**, *17*, e0264969. [CrossRef] [PubMed]
66. Nokhala, A.; Siddiqui, M.J.; Ahmed, Q.U.; Ahamad Bustamam, M.S.; Zakaria, Z.A. Investigation of α -glucosidase inhibitory metabolites from *Tetracera scandens* leaves by GC-MS metabolite profiling and docking studies. *Biomolecules.* **2020**, *10*, 287. [CrossRef]
67. Wan-Nadilah, W.A.; Akhtar, M.T.; Shaari, K.; Khatib, A.; Hamid, A.A.; Hamid, M. Variation in the metabolites and α -glucosidase inhibitory activity of *Cosmos caudatus* at different growth stages. *BMC Complement. Altern. Med.* **2019**, *19*, 1–15. [CrossRef]
68. Saleh, M.S.; Jalil, J.; Mustafa, N.H.; Ramli, F.F.; Asmadi, A.Y.; Kamisah, Y. UPLC-MS-based metabolomics profiling for α -glucosidase inhibiting property of *Parkiaspeciosa* pods. *Life.* **2021**, *11*, 78. [CrossRef]
69. William, J.; John, P.; Mumtaz, M.W.; Ch, A.R.; Adnan, A.; Mukhtar, H.; Sharif, S.; Raza, S.A.; Akhtar, M.T. Antioxidant activity, α -glucosidase inhibition and phytochemical profiling of *Hyophorbelagenicaulis* leaf extracts. *PeerJ.* **2019**, *7*, e7022. [CrossRef]
70. Abo-Salem, O.M.; Ali, T.M.; Harisa, G.I.; Mehanna, O.M.; Younos, I.H.; Almalki, W.H. Beneficial effects of (–)-epigallocatechin-3-O-gallate on diabetic peripheral neuropathy in the rat model. *J. Biochem. Mol. Toxicol.* **2020**, *34*, e22508. [CrossRef]
71. Kamiyama, O.; Sanae, F.; Ikeda, K.; Higashi, Y.; Minami, Y.; Asano, N.; Adachi, I.; Kato, A. In vitro inhibition of α -glucosidases and glycogen phosphorylase by catechingallates in green tea. *Food Chem.* **2010**, *122*, 1061–1066. [CrossRef]
72. Gamberucci, A.; Konta, L.; Colucci, A.; Giunti, R.; Magyar, J.E.; Mandl, J.; Banhegyi, G.; Bendetti, A.; Csala, M. Green tea flavonols inhibit glucosidase II. *Biochem. Pharmacol.* **2006**, *72*, 640–646. [CrossRef]
73. Tadera, K.; Minami, Y.; Takamatsu, K.; Matsuoka, T. Inhibition of α -glucosidase and α -amylase by flavonoids. *J. Nutr. Sci. Vitaminol.* **2006**, *52*, 149–153. [CrossRef]
74. Cai, Y.; Wu, L.; Lin, X.; Hu, X.; Wang, L. Phenolic profiles and screening of potential α -glucosidase inhibitors from *Polygonum aviculare* L. leaves using ultra-filtration combined with HPLC-ESI-qTOF-MS/MS and molecular docking analysis. *Ind. Crops Prod.* **2020**, *154*, 112673. [CrossRef]
75. Quaresma, D.M.; Justino, A.B.; Sousa, R.M.; Munoz, R.A.; de Aquino, F.J.; Martins, M.M.; Goulart, L.R.; Pivatto, M.; Espindola, F.S.; de Oliveira, A. Antioxidant compounds from *Banisteriopsis argyrophylla* leaves as α -amylase, α -glucosidase, lipase, and glycation inhibitors. *Bioorganic Chem.* **2020**, *105*, 104335. [CrossRef] [PubMed]

76. Amel, Z.; Nabila, B.B.; Nacéra, G.; Fethi, T.; Fawzia, A.B. Assessment of phytochemical composition and antioxidant properties of extracts from the leaf, stem, fruit and root of *Pistacia lentiscus* L. *Int. J. Pharmacogn. Phytochem. Res.* **2016**, *8*, 627–633.
77. ElezGarofulić, I.; Kruk, V.; Martić, A.; Martić, I.; Zorić, Z.; Pedisić, S.; Dragović, S.; Dragović-Uzelac, V. Evaluation of polyphenolic profile and antioxidant activity of *Pistacia lentiscus* L. leaves and fruit extract obtained by optimized microwave-assisted extraction. *Foods* **2020**, *9*, 1556. [[CrossRef](#)]
78. Aissat, A.K.; Chaher-Bazizi, N.; Richard, T.; Kilani-Atmani, D.; Pedrot, E.; Renouf, E.; Atmani, D.; Fonayet, J.V. Analysis of individual anthocyanins, flavanols, flavonols and other polyphenols in *Pistacia lentiscus* L. fruits during ripening. *J. Food Compos. Anal.* **2020**, *106*, 104286. [[CrossRef](#)]
79. Sehaki, C.; Jullian, N.; Choque, E.; Dauwe, R.; Fontaine, J.X.; Molinie, R.; Ayati, F.; Fernane, F.; Gontier, E. Profiling of Essential Oils from the Leaves of *Pistacia lentiscus* Collected in the Algerian Region of Tizi-Ouzou: Evidence of Chemical Variations Associated with Climatic Contrasts between Littoral and Mountain Samples. *Molecules* **2022**, *27*, 4148. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.